The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 10, 2026

Filed:

Nov. 27, 2020
Applicant:

Kymab Limited, Babraham, GB;

Inventors:

Matthew Wake, Babraham, GB;

Volker Germaschewski, Babraham, GB;

Igor Theurl, Babraham, GB;

Jonathan Leslie Papworth, Babraham, GB;

Delphine Meynard, Paris, FR;

Assignee:

Kymab Limited, Cambridge, GB;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 38/17 (2006.01); A61K 38/22 (2006.01); A61K 39/395 (2006.01); A61K 48/00 (2006.01); A61P 7/06 (2006.01);
U.S. Cl.
CPC ...
C07K 16/28 (2013.01); A61K 38/179 (2013.01); A61K 38/22 (2013.01); A61K 39/3955 (2013.01); A61K 48/005 (2013.01); A61P 7/06 (2018.01); C07K 2317/21 (2013.01);
Abstract

Antibodies to the enzyme matriptase-2 (MTP-2) are presented. Inhibiting MTP-2 reduces uptake of dietary iron and reduces the release of iron from cellular stores in the body. Inhibitors of MTP-2 (such as antibodies to the serine protease domain) can be used to treat iron overload, which is a feature of diseases such as beta-thalassaemia and which otherwise leads to toxic accumulation of iron. Combination of an MTP-2 inhibitor with an activin receptor ligand trap, or with erythropoietin, provides additional therapeutic effects.


Find Patent Forward Citations

Loading…